New Therapy for Management of Heart Failure
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.contributor.author | Ose, Haruka | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | |
| dc.contributor.opponent | Halasi, Barbara Dóra | |
| dc.contributor.opponent | Megyeri, Attila | |
| dc.contributor.opponentdept | Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet | |
| dc.contributor.opponentdept | Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.date.accessioned | 2024-04-17T10:27:37Z | |
| dc.date.available | 2024-04-17T10:27:37Z | |
| dc.date.created | 2023-02-10 | |
| dc.description.abstract | The article outlines treatments for different types of heart failure: HFrEF, HFmrEF, and HFpEF. Medications like ACE inhibitors, MRAs, beta-blockers, and ARNI are recommended for HFrEF, while HFmrEF patients may benefit from treatments used for HFrEF. However, effective medications for HFpEF are lacking. New drugs such as SGLT2 inhibitors, omecamtiv mecarbil, and vericiguat show promise for HFrEF. ARNI, notably effective in reducing exacerbations and mortality, is expected to become a cornerstone treatment. Additionally, drugs like ivabradine and SGLT2 inhibitors offer added benefits, contributing to the evolving landscape of heart failure management. There needs further research and trials to further increase survival rate of heart failure patients. | |
| dc.description.course | általános orvos | |
| dc.description.courselang | angol | |
| dc.description.degree | egységes, osztatlan | |
| dc.format.extent | 36 | |
| dc.identifier.uri | https://hdl.handle.net/2437/368897 | |
| dc.language.iso | en | |
| dc.rights.access | Hozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében. | |
| dc.subject | Heart failure | |
| dc.subject | HFrEF | |
| dc.subject | HFpEF | |
| dc.subject | HFmrEF | |
| dc.subject | NYHA | |
| dc.subject | ACC/AHA | |
| dc.subject | Left ventricular hypertrophy | |
| dc.subject | Novel treatment | |
| dc.subject | Sacubitril-valsartan | |
| dc.subject | Ivabradine | |
| dc.subject | Sodium glucose co-transporter 2 inhibitors | |
| dc.subject | Vericiguat | |
| dc.subject | Omecamtiv mecarbil | |
| dc.subject | Sodium ziroconium cyclosilicate | |
| dc.subject | Tafamidis | |
| dc.subject | Sildenafil | |
| dc.subject.dspace | Medicine::Pharmacology | |
| dc.title | New Therapy for Management of Heart Failure |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nincs kép
- Név:
- Thesis Ose Haruka.pdf
- Méret:
- 983.29 KB
- Formátum:
- Adobe Portable Document Format
- Leírás:
Engedélyek köteg
1 - 1 (Összesen 1)
Nincs kép
- Név:
- license.txt
- Méret:
- 1.94 KB
- Formátum:
- Item-specific license agreed upon to submission
- Leírás: